Wednesday, July 29, 2009
Comparative Effectiveness Research and Evidence-Based Decision Making Across Four Countries: The U.K., Germany, France, and Australia - The Commonwealth Fund
Comparative Effectiveness Research and Evidence-Based Decision Making Across Four Countries: The U.K., Germany, France, and Australia - The Commonwealth Fund: "Comparative Effectiveness Research and Evidence-Based Decision Making Across Four Countries: The U.K., Germany, France, and Australia"
Tuesday, July 28, 2009
Microsatellite Instability and Mismatch Repair Protein Defects in Ovarian Epithelial Neoplasms in Patients 50 Years of Age and Younger
Microsatellite Instability and Mismatch Repair Protein Defects in Ovarian Epithelial Neoplasms in Patients 50 Years of Age and Younger: "This study demonstrates a 10% rate of MMR-deficient ovarian cancer in women <50 years of age. MMR-deficient ovarian cancer is frequently associated with loss of expression of MSH2 and MSH6 proteins and clear cell histology. The occurrence of MMR inactivation in a significant proportion of ovarian clear cell carcinomas (17% in this study) suggests that this tumor may warrant targeted testing in women < 50 years of age."
Monday, July 27, 2009
Ovarian Cancer Tests Flawed, in Need of New Design, Says Stanford Study
Ovarian Cancer Tests Flawed, in Need of New Design, Says Stanford Study: "Ovarian Cancer Tests Flawed, in Need of New Design, Says Stanford Study"
BioMed Central | Full text | Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
BioMed Central | Full text | Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.: "Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study"
Sunday, July 26, 2009
Saturday, July 25, 2009
Friday, July 24, 2009
Thursday, July 23, 2009
Wednesday, July 22, 2009
European Journal of Human Genetics - Genomics and breast cancer: the different levels of inherited susceptibility
European Journal of Human Genetics - Genomics and breast cancer: the different levels of inherited susceptibility: "Other syndromes discussed in this review which may be associated with a moderately increased breast cancer risk include neurofibromatosis type 1 and Nijmegen breakage syndrome mutation carriers, and the slight increase in risk associated with Lynch syndrome is referred to, although the relative increase in breast cancer risk in Lynch syndrome is debated and generally considered to be low, but may vary with the different genes involved."
Heartfelt Tales by Physicians and Patients Inspire a Unique Online National Magazine - MarketWatch
Heartfelt Tales by Physicians and Patients Inspire a Unique Online National Magazine - MarketWatch: "Patients have written equally powerful and sometimes humorous stories about such topics as anger (when doctors miss an ovarian-cancer diagnosis)"
Tuesday, July 21, 2009
The future of cancer screening. [Prim Care. 2009] - PubMed Result
The future of cancer screening. [Prim Care. 2009] - PubMed Result: ": Prim Care. 2009 Sep;36(3):623-39.
The future of cancer screening.
Collins LG, Wynn DT, Barash JH.
Division of Geriatric Medicine, Department of Family and Community Medicine, Jefferson Medical College, Thomas Jefferson University, 1015 Walnut Street, Suite 401, Philadelphia, PA 19107, USA. Lauren.Collins@jefferson.edu
Lung and ovarian cancers are two of the most common and deadly cancers affecting men and women in the United States. The potential impact of an effective screening modality for early detection of these cancers is enormous. Yet, to date, no screening tool has been proven to reduce mortality in asymptomatic individuals, and no major organization endorses current modalities for screening for these cancers. Novel approaches, potentially relying on genomics and proteomics, may be the future for early detection of these deadly cancers."
Colorectal Cancer Risk Perception on the Basis of Genetic Test Results in Individuals at Risk for Lynch Syndrome -- Grover et al., 10.1200/JCO.2008.18.6940 -- Journal of Clinical Oncology
"Conclusion: Patients at risk for Lynch syndrome with an indeterminate genetic test result may be falsely reassured. It is important that health care providers continue to discuss the implications of uninformative results on lifetime cancer risk."
Monday, July 20, 2009
Sunday, July 19, 2009
Article Submission by Kat Sanders: CA125 and the Role of a Radiologist in Treating Cancer
CA125 and the Role of a Radiologist in Treating Cancer
http://becomingaradiologist.org/
There are various factors that cause cancer, and in the fight back against this terrible disease, mankind has discovered and invented some of the best methods of treating and managing it. One such aspect is CA125, also known as Cancer Antigen 125, a marker that can potentially detect the early stages of ovarian cancer in women. More than the diagnosis however, the role of CA125 comes to the fore in the continuing treatment and future prognosis. It helps your oncologist detect if your cancer has the potential to return or if you are well on the way to recovery.
As with any cutting edge treatment, CA125 has come it for its share of criticism when it is used as a marker to diagnose ovarian cancer. While it has been accepted as the standard in determining the future prognosis of a patient who has been diagnosed with ovarian cancer and treated for the same, there are doubts over how effective it is in helping to determine the presence of cancerous growths in the ovary. This is because women with elevated levels of CA125 in their blood are not necessarily suffering from ovarian cancer or are at risk for the disease. Also, there is no evidence to prove that the absence of or low level of CA125 is enough to rule out the possibility of ovarian cancer.
Although CA125 is primarily known for its use in treating and managing ovarian cancer, there is evidence to show that it is helpful in diagnosing other kinds of cancers like those that originate in the endometrium, breast, fallopian tubes, lungs and the gastrointestinal tract.
Recent research has found that Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is more effective than CA125 in helping to assess the recurrence of ovarian cancer and the efficacy of the treatment being followed by those who are affected by this disease.
Even so, CA125 is extremely useful in monitoring therapy for ovarian cancer and in determining the recurrence of the cancer over a period of time.
By-line:
This article is written by Kat Sanders, who regularly blogs on the topic of radiologist technician at her blog "The Overwhelmed Student" Blog. She welcomes your comments and questions at her email address: katsanders25@gmail.com.
http://becomingaradiologist.org/
Saturday, July 18, 2009
Menopausal HT and Ovarian Cancer: Causal Role Remains Unclear - Commentary on the Danish study
This is a commentary on the Danish study.
Friday, July 17, 2009
Thursday, July 16, 2009
Wednesday, July 15, 2009
Market Report -- In Play (JNJ): Trabectedin (Yondelis)
Market Report -- In Play (JNJ): Briefing.com Business News - MSN Money: "Johnson & Johnson: Centocor Ortho Biotech issues statement on the FDA ODAC opinion regarding trabectedin for relapsed ovarian cancer Co announces based on the data presented today, the FDA Oncologic Drugs Advisory Committee recommended that the combination of trabectedin when administered with DOXIL did not provide a sufficient benefit-risk profile for the treatment of relapsed ovarian cancer. Centocor Ortho Biotech Products continues to believe trabectedin has an important role in the treatment of recurrent ovarian cancer. The company remains committed to working with the FDA to address the committee's concerns. The committee provides non-binding recommendations based on its evaluation. The final decision regarding approval of the drug will be made by the FDA."
FDA panel recommends against Centocor’s trabectedin (ovarian cancer)
The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted Wednesday not to recommend approval of trabectedin, an experimental cancer treatment being developed by Centocor Ortho Biotech.
Centocor Ortho Biotech of Horsham, Pa., is seeking approval of trabectedin as part of a combination therapy with the cancer drug Doxil for patients with relapsed ovarian cancer.
FDA committee recommendations are nonbinding, but the federal agency generally follows the advice of its advisory panels when making a final determination......Under a licensing agreement with PharmaMar SAU of Spain, Centocor has worldwide marketing rights for trabectedin except in Europe and Japan, where the product is marketed as Yondelis by PharmaMar.
Subscribe to:
Posts
(
Atom
)
